Insulinoma Workup

  • Author: Zonera Ashraf Ali, MD; Chief Editor: Jules E Harris, MD   more...
 
Updated: Nov 23, 2011
 

Laboratory Studies

  • Failure of endogenous insulin secretion to be suppressed by hypoglycemia is the hallmark of an insulinoma. Thus, the finding of inappropriately elevated levels of insulin in the face of hypoglycemia is the key to diagnosis. Considering the reference range, the fasting plasma levels of insulin, C-peptide, and, to a lesser degree, proinsulin need not be elevated in insulinoma patients in absolute terms.
  • A study by Wiesli et al found that proinsulin, C-peptide, and insulin are all released by insulinoma cells in response to arterial calcium stimulation; however, chromogranin A (CgA) and neuron-specific enolase (NSE) are not released. The study also concluded that pancreatic polypeptide may be released by healthy islet cells after calcium stimulation.[13]
  • The biochemical diagnosis is established in 95% of patients during prolonged fasting (up to 72 h) when the following parameters are found:
    • Serum insulin levels of 10 µU/mL or more (normal < 6 µU/mL)
    • Glucose levels of less than 40 mg/dL
    • C-peptide levels exceeding 2.5 ng/mL (normal < 2 ng/mL)
    • Proinsulin levels greater than 25% (or up to 90%) that of immunoreactive insulin
    • Screening for sulfonylurea negative
  • Stimulation tests no longer are recommended. The intravenous application of tolbutamide, glucagon, or calcium can be hazardous, as they may induce prolonged and refractory hypoglycemia.
  • Prolonged (ie, 72 h) supervised fast in hospitalized patients provides the most reliable results.
    • The calculation of ratios of insulin (µU/mL) to plasma glucose (mg/dL) is diagnostic.
    • Healthy patients maintain a rate of less than 0.25. Obese patients may have a slightly higher rate.
    • In patients with insulinoma, the ratio rises during fasting.
  • In a study from the Netherlands, a positive Whipple triad on a prolonged fasting test, in combination with an insulin/C-peptide ratio < 1, had a sensitivity of 88.9% and a specificity of 100% for the diagnosis of insulinoma.[14]
  • The presence of MEN 1 must be evaluated by excluding the following:
    • Hyperprolactinemia due to a pituitary adenoma
    • Hyperparathyroidism due to parathyroid hyperplasia
    • Hypergastrinemia due to a gastrinoma
Next

Imaging Studies

  • Start imaging studies only after the diagnosis has been confirmed biochemically, because 80% of insulinomas are less than 2 cm in size and may not be visible by CT scan or transabdominal ultrasonography.
  • Successful preoperative tumor localization is achieved in about 60% of patients.[15]
    • Some experienced surgeons perform only transabdominal ultrasound preoperatively.
    • Other surgeons argue that the preoperative localization of insulinomas is not necessary at all because surgical exploration and intraoperative ultrasonography identify more than 90% of tumors.[16]
    • Thus, the extent to which one attempts to define the anatomy of the beta cell lesion before surgery is a matter of judgment.
  • Helical or multislice CT scan has 82-94% sensitivity. In one study, dual-phase helical CT proved more sensitive than single-phase for detection of insulinoma; in addition, image acquisition in the arterial phase proved more helpful than acquisition during the portal-venous phase.[17]
  • MRI with gadolinium can be helpful in detecting a tumor in 85% of cases. One case report suggests that diffusion-weighted MRI can be useful for detecting and localizing small insulinomas, especially for those with no hypervascular pattern.[18]
  • The accuracy of selective arteriography is 82%, although affected by a false-positive rate of 5%. Many experts see it as the best overall preoperative localization procedure.
  • Arteriography with catheterization of small arterial branches of the celiac system combined with calcium injections (which stimulate insulin release from neoplastic tissue but not from normal islets), and simultaneous measurements of hepatic vein insulin during each selective calcium injection localizes tumors in 47% of patients.
  • The sensitivity of somatostatin receptor scintigraphy is 60%, although many insulinomas lack somatostatin receptor subtype 2 for successful identification.
  • Endoscopic ultrasonography detects 77% of insulinomas in the pancreas.[19, 20, 21] The yield can be higher if it is done in combination with CT scan. A majority of sporadic insulinomas will be detected and localized by a combination of these two investigative means.
  • Real-time transabdominal high-resolution ultrasonography has 50% sensitivity.
  • Intraoperative transabdominal high-resolution ultrasonography with the transducer wrapped in a sterile rubber glove and passed over the exposed pancreatic surface detects more than 90% of insulinomas.
  • Performing a preoperative study to localize the tumor followed by intraoperative ultrasonography and a physical examination is not unreasonable.
  • Insulinomas have been shown to have a very high density of glucagon-like peptide-1 receptors (GLP-1R), and radiolabeling with an111 In-labeled GLP-1R agonist (111 In-DOTA-exendin-4) has successfully been used to localize small insulinomas both preoperatively and, with the use of a gamma probe, intraoperatively.[22] Somatostatin receptor target imaging can diagnosis malignant insulinomas missed by GLP-1 target imaging because these malignancies often lack GLP-1 receptors.[23]
Previous
Next

Other Tests

  • Preoperative portal venous sampling is obsolete as a routine investigation because of a high complication rate (10%), but it may be used when all other imaging procedures fail and surgical exploration findings are negative.
  • Localization with anti-insulin labeled with iodine-131 was achieved in 50% of patients, with a 37.5% false-positive rate. Therefore, it is not recommended.
  • Recently, endoscopic ultrasound-guided fine-needle aspiration biopsy has been described in an insulinoma. It is a technique combining endoscopic ultrasonography with local tumor biopsy and may be indicated when the tissue diagnosis must be established preoperatively.
  • Laparoscopic ultrasonography with eventual tumor biopsy may be used in rare cases when other localization techniques failed.
Previous
Next

Histologic Findings

Insulinomas are solitary tumors in 90% of patients. In MEN 1 syndrome, multiple microinsulinomas and macroinsulinomas are found, although hypoglycemia may be caused by a single tumor. The tumors are distributed evenly throughout the pancreas. Tumor size does not relate to the severity of clinical symptoms. Ectopic insulinomas may be found in the ligament of Treitz.

No histologic criteria are available to distinguish benign from malignant insulinomas. Malignant tumors are usually larger (average size 6.2 cm), and a third of them have metastasized to the liver. Insulinoma tumor cells contain less insulin and secretory granules than normal B cells but higher levels of proinsulin. Atypical granules, or even agranular cells, are frequent. The clinical response to diazoxide and somatostatin correlates with the frequency and type of granules.

Previous
Next

Staging

A recent TNM staging system has not been validated yet for insulinoma tumors.

Previous
Proceed to Treatment & Management
 
 
Contributor Information and Disclosures
Author

Zonera Ashraf Ali, MD  Consulting Staff, Main Line Oncology Hematology Associates, Lankenau Cancer Center

Zonera Ashraf Ali, MD is a member of the following medical societies: American Society of Clinical Oncology and American Society of Hematology

Disclosure: Nothing to disclose.

Coauthor(s)

Klaus Radebold, MD, PhD  Research Associate, Department of Surgery, Yale University School of Medicine

Klaus Radebold, MD, PhD is a member of the following medical societies: American Gastroenterological Association and New York Academy of Sciences

Disclosure: Nothing to disclose.

Specialty Editor Board

Pradyumna D Phatak, MBBS, MD  Chair, Division of Hematology and Medical Oncology, Rochester General Hospital; Clinical Professor of Oncology, Roswell Park Cancer Institute

Pradyumna D Phatak, MBBS, MD, is a member of the following medical societies: American Society of Hematology

Disclosure: Novartis Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rajalaxmi McKenna, MD, FACP  Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD  Clinical Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine; Consulting Staff, Arizona Cancer Center

Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research

Disclosure: GlobeImmune Salary Consulting

References

  1. Phan GQ, Yeo CJ, Hruban RH, et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. Sep-Oct 1998;2(5):472-82. [Medline].

  2. Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. Oct 2009;89(5):1105-21. [Medline].

  3. Dadan J, Wojskowicz P, Wojskowicz A. Neuroendocrine tumors of the pancreas. Wiad Lek. 2008;61(1-3):43-7. [Medline].

  4. Larijani B, Aghakhani S, Lor SS, Farzaneh Z, Pajouhi M, Bastanhagh MH. Insulinoma in Iran: a 20-year review. Ann Saudi Med. Nov-Dec 2005;25(6):477-80. [Medline].

  5. Fernandez-Cruz L, Blanco L, Cosa R, Rendon H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?. World J Surg. May 2008;32(5):904-17. [Medline].

  6. Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. Mar 1999;106(3):307-10. [Medline].

  7. Schmitt J, Boullu-Sanchis S, Moreau F, Drui S, Louis B, Chabrier G, et al. Association of malignant insulinoma and type 2 diabetes mellitus: a case report. Ann Endocrinol (Paris). Feb 2008;69(1):69-72. [Medline].

  8. Hrascan R, Pecina-Slaus N, Martic TN, Colic JF, Gall-Troselj K, Pavelic K. Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas. J Neuroendocrinol. Aug 2008;20(8):1015-22. [Medline].

  9. Waickus CM, de Bustros A, Shakil A. Recognizing factitious hypoglycemia in the family practice setting. J Am Board Fam Pract. Mar-Apr 1999;12(2):133-6. [Medline].

  10. Redmon JB, Nuttall FQ. Autoimmune hypoglycemia. Endocrinol Metab Clin North Am. Sep 1999;28(3):603-18, vii. [Medline].

  11. Eriguchi N, Aoyagi S, Hara M, et al. Nesidioblastosis with hyperinsulinemic hypoglycemia in adults: report of two cases. Surg Today. 1999;29(4):361-3. [Medline].

  12. Starke A, Saddig C, Kirch B, Tschahargane C, Goretzki P. Islet hyperplasia in adults: challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycemia syndrome. World J Surg. May 2006;30(5):670-9. [Medline].

  13. Wiesli P, Uthoff H, Perren A, et al. Are biochemical markers of neuroendocrine tumors coreleased with insulin following local calcium stimulation in patients with insulinomas?. Pancreas. Oct 2011;40(7):995-9. [Medline].

  14. van Bon AC, Benhadi N, Endert E, Fliers E, Wiersinga WM. Evaluation of endocrine tests. D: the prolonged fasting test for insulinoma. Neth J Med. Jul-Aug 2009;67(7):274-8. [Medline].

  15. Boukhman MP, Karam JM, Shaver J, et al. Localization of insulinomas. Arch Surg. Aug 1999;134(8):818-22; discussion 822-3. [Medline].

  16. Hashimoto LA, Walsh RM. Preoperative localization of insulinomas is not necessary. J Am Coll Surg. Oct 1999;189(4):368-73. [Medline].

  17. Liu Y, Song Q, Jin HT, Lin XZ, Chen KM. The value of multidetector-row CT in the preoperative detection of pancreatic insulinomas. Radiol Med. Sep 30 2009;[Medline].

  18. Anaye A, Mathieu A, Closset J, Bali MA, Metens T, Matos C. Successful preoperative localization of a small pancreatic insulinoma by diffusion-weighted MRI. JOP. Sep 4 2009;10(5):528-31. [Medline].

  19. Kirkeby H, Vilmann P, Burcharth F. Insulinoma diagnosed by endoscopic ultrasonography-guided biopsy. J Laparoendosc Adv Surg Tech A. Jun 1999;9(3):295-8. [Medline].

  20. Proye C, Malvaux P, Pattou F, et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery. Dec 1998;124(6):1134-43; discussion 1143-4. [Medline].

  21. McLean A. Endoscopic ultrasound in the detection of pancreatic islet cell tumours. Cancer Imaging. Mar 29 2004;4(2):84-91. [Medline].

  22. Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas. J Clin Endocrinol Metab. Oct 9 2009;[Medline].

  23. Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. Jul 2011;52(7):1073-8. [Medline].

  24. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion. 2000;62 Suppl 1:84-91. [Medline].

  25. Limmer S, Huppert PE, Juette V, Lenhart A, Welte M, Wietholtz H. Radiofrequency ablation of solitary pancreatic insulinoma in a patient with episodes of severe hypoglycemia. Eur J Gastroenterol Hepatol. Sep 2009;21(9):1097-101. [Medline].

  26. Lo CY, Lam KY, Fan ST. Surgical strategy for insulinomas in multiple endocrine neoplasia type I. Am J Surg. Apr 1998;175(4):305-7. [Medline].

  27. Dexter SP, Martin IG, Leindler L, et al. Laparoscopic enucleation of a solitary pancreatic insulinoma. Surg Endosc. Apr 1999;13(4):406-8. [Medline].

  28. Moscetti L, Saltarelli R, Giuliani R, et al. Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature. Tumori. Nov-Dec 2000;86(6):475-9. [Medline].

  29. Smith MC, Liu J, Chen T, et al. OctreoTher: ongoing early clinical development of a somatostatin- receptor-targeted radionuclide antineoplastic therapy. Digestion. 2000;62 Suppl 1:69-72. [Medline].

  30. Bourcier ME, Sherrod A, DiGuardo M, Vinik AI. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab. Sep 2009;94(9):3157-62. [Medline].

  31. Gonzalez-Gonzalez A, Recio-Cordova JM. Liver metastases 9 years after removal of a malignant insulinoma which was initially considered benign. JOP. 2006;7(2):226-9. [Full Text].

  32. Abboud B, Boujaoude J. Occult sporadic insulinoma: localization and surgical strategy. World J Gastroenterol. Feb 7 2008;14(5):657-65. [Medline].

  33. Ahlman H, Wangberg B, Jansson S, et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion. 2000;62 Suppl 1:59-68. [Medline].

  34. Begu-Le Corroller A, Valero R, Moutardier V, Henry JF, Le Treut YP, Gueydan M. Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: A retrospective 35-year study of 12 patients. Diabetes Metab. Jun 13 2008;[Medline].

  35. Diagnosis and management of pancreatic endocrine tumors. In: De Vita V, Lawrence T, Rosenberg S. Cancer. Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2008:1706-15.

  36. Faggiano A, Mansueto G, Ferolla P, Milone F, del Basso de Caro ML, Lombardi G, et al. Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. J Endocrinol Invest. Mar 2008;31(3):216-23. [Medline].

  37. Grant CS. Surgical aspects of hyperinsulinemic hypoglycemia. Endocrinol Metab Clin North Am. Sep 1999;28(3):533-54. [Medline].

  38. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol. 1999;10 Suppl 4:170-6. [Medline].

  39. Keymeulen B, Bossuyt A, Peeters TL, Somers G. 111In-octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment?. Ann Nucl Med. Aug 1995;9(3):149-52. [Medline].

  40. Kuzin NM, Egorov AV, Kondrashin SA, et al. Preoperative and intraoperative topographic diagnosis of insulinomas. World J Surg. Jun 1998;22(6):593-7; discussion 597-8. [Medline].

  41. Le Roith D. Tumor-induced hypoglycemia. N Engl J Med. Sep 2 1999;341(10):757-8. [Medline].

  42. Molven A, Matre GE, Duran M, Wanders RJ, Rishaug U, Njolstad PR. Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. Diabetes. Jan 2004;53(1):221-7. [Medline].

  43. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion. 2000;62 Suppl 1:73-8. [Medline].

  44. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000;62 Suppl 1:79-83. [Medline].

 
Previous
Next
 
CT scan image with oral and intravenous contrast in a patient with biochemical evidence of insulinoma. The 3-cm contrast-enhancing neoplasm (arrow) is seen in the tail of the pancreas (P) posterior to the stomach (S) (Yeo, 1993).
Endoscopic ultrasonography in a patient with an insulinoma. The hypoechoic neoplasm (arrows) is seen in the body of the pancreas anterior to the splenic vein (SV) (Rosch, 1992).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.